Literature DB >> 941790

A novel relationship between plasma kininogen and rheumatoid.

J N Sharma, I J Zeitlin, P M Brooks, W C Dick.   

Abstract

Plasma kininogen levels in the peripheral venous blood of untreated patients with active rheumatoid disease was found to be more than twice the levels measured in healthy normal individuals or in convalescing uncomplicated fracture patients. Treatment with oral indomethacin or aspirin lowered the kininogen levels nearly to normal. Sequential studies showed that the fall in kininogen was very rapid, occurring within 1-2 hours of ingestion of drug, and was parallelled by reduction in the clinical indices of inflammation. Control studies showed that the kininogen changes were not due to changes in plasma volume or non-specific changes in plasma protein concentration. Indomethacin treatment had no effect on plasma kininogen levels in healthy volunteers. The significance of this finding will be discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 941790     DOI: 10.1007/bf01972199

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  11 in total

1.  Pain-producing substance in human inflammatory exudates and plasma.

Authors:  D ARMSTRONG; J B JEPSON; C A KEELE; J W STEWART
Journal:  J Physiol       Date:  1957-02-15       Impact factor: 5.182

2.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

3.  Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid.

Authors:  H W Emori; G D Champion; R Bluestone; H E Paulus
Journal:  Ann Rheum Dis       Date:  1973-09       Impact factor: 19.103

4.  Intracellular enzymes and kinin enzymes in synovial fluid in joint diseases. Origin and relation to disease category.

Authors:  M K Jasani; M Katori; G P Lewis
Journal:  Ann Rheum Dis       Date:  1969-09       Impact factor: 19.103

5.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

6.  Urates and kinin formation in synovial fluid.

Authors:  V Eisen
Journal:  Proc R Soc Med       Date:  1966-04

7.  Determination of plasmakinin & kininogen levels in man.

Authors:  W E Brocklehurst; I J Zeitlin
Journal:  J Physiol       Date:  1967-07       Impact factor: 5.182

8.  Determination of plasma kininogen, plasma kininase and erythrocyte kininase in men with rheumatoid arthritis.

Authors:  K Briseid; O K Dyrud; S F Rinvik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1966

9.  The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies.

Authors:  K L Melmon; M E Webster; S E Goldfinger; J E Seegmiller
Journal:  Arthritis Rheum       Date:  1967-02

10.  Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis.

Authors:  P Lee; J Webb; J Anderson; W W Buchanan
Journal:  Br Med J       Date:  1973-06-23
View more
  4 in total

1.  Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy.

Authors:  J N Sharma; A P Yusof
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

2.  Functionally active alpha2-macroglobulin and kinen release in synovial fluids of rheumatoid arthritis.

Authors:  U Hamberg; E Vahtera; L Moilanen
Journal:  Agents Actions       Date:  1978-01

3.  Age-related differences in plasma proteins: how plasma proteins change from neonates to adults.

Authors:  Vera Ignjatovic; Cera Lai; Robyn Summerhayes; Ulrike Mathesius; Sherif Tawfilis; Matthew A Perugini; Paul Monagle
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

4.  Characterization of chikungunya virus induced host response in a mouse model of viral myositis.

Authors:  Rekha Dhanwani; Mohsin Khan; Vinay Lomash; Putcha Venkata Lakshmana Rao; Hinh Ly; Manmohan Parida
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.